A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol
given in the evening time once a day vs the combination of dorzamalide and timolol twice a
day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week
Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide
Merck Frosst Canada Ltd.
Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open
angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic
nerve perfusion. The objectives of this study are to learn the effects of dorzolamide on the
retinal and optic nerve blood flow of glaucoma patients.
The present study is a prospective, randomized, double-masked, crossover design study of
newly diagnosed or already treated patients with early glaucoma.
The investigators will check ocular blood flow parameters using the Canon Laser Blood
Flowmeter (CLBF), used to evaluate retinal arteriole blood flow, and the Heidelberg retinal
flowmeter (HRF), which measures blood flow through capillary beds in the retina and optic
Any demonstrated improvements to retinal and optic nerve blood flow with dorzolamide, will
mean that the drug may protect against ischaemic nerve and retinal damage. Any documented
improvement in flow could lead to a major change in the management of glaucoma patients as
well as other retinal ischemic diseases such as diabetic retinopathy and central retinal
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.